Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 13/20 | 0.49 |
| ▸ | PLAU | P00749 | 2/20 | 0.43 |
| ▸ | ERCC1 | P07992 | 2/20 | 0.43 |
| ▸ | FEN1 | P39748 | 2/20 | 0.43 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.37 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4584950 | 0.91 | ADORA2A (0.49) | ADORA2APLAUERCC1FEN1ERCC4 | |
| SCHEMBL4585715 | 0.87 | ADORA2A (0.45) | ADORA2APLAUERCC1FEN1ERCC4 | |
| SCHEMBL4584433 | 0.85 | ADORA2A (0.56) | ADORA2APLAUADORA2BADORA1 | |
| SCHEMBL4585883 | 0.81 | ADORA2A (0.65) | ADORA2AADORA2BADORA1 | |
| SCHEMBL29987316 | 0.81 | ADORA2A (0.65) | ADORA2AADORA2BADORA1 | |
| SCHEMBL4584998 | 0.79 | ADORA2A (0.57) | ADORA2APLAUADORA2BADORA1MEN1 | |
| SCHEMBL4585018 | 0.79 | ADORA2A (0.45) | ADORA2APLAUERCC1FEN1ERCC4 | |
| SCHEMBL4584602 | 0.78 | ADORA2A (0.48) | ADORA2AADORA2BADORA1MEN1KMT2A | |
| SCHEMBL28470700 | 0.78 | ADORA2A (0.48) | ADORA2AADORA2BADORA1 | |
| SCHEMBL4583598 | 0.77 | ADORA2A (0.55) | ADORA2APLAUADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407961-B2 | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2008-08-05 | — | — | US | disclosed |
| CN-1871231-A | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC (JP) | 2006-11-29 | — | — | CN | disclosed |
| US-20050113387-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113387-A1 | Pyrazine derivatives and pharmaceutical use thereof | ADORA2A, P2RX5, ADORA1 | ADORA2A 1/4885PLAU 1420/4885ERCC1 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.